<DOC>
	<DOC>NCT02217033</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of consuming "R" on quality of life in the areas of insomnia, fatigue, and depression in female breast cancer patients receiving multi-cycle adjuvant chemotherapy.</brief_summary>
	<brief_title>Effects of 'R' (Electro-kinetic Beverage) on Insomnia, Fatigue, and Depression in Breast Cancer Patients Having Adjuvant Chemo</brief_title>
	<detailed_description>Female breast cancer patients eligible for adjuvant therapy with four cycles of Taxotere and Cytoxan chemotherapy after surgery will be enrolled for the study. Eligible subjects will begin to consume either "R" or purified water (placebo) just prior to the 1st cycle of chemotherapy. Subjects will continue to consume either "R" or placebo through Cycle 1, Cycle 2, Cycle 3, Cycle 4, and for an additional 12 weeks after completing chemotherapy. Study procedures will include clinical lab assessments, analysis of inflammatory markers, RNA biomarkers, adverse events, subject diary, and quality of life measurements for insomnia, fatigue and depression.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<criteria>Female, nonsmokers ≥ 18 years of age Histologically or cytologically confirmed diagnosis of Stage I or II adenocarcinoma of the breast and a candidate for adjuvant chemotherapy Scheduled to receive 4 cycles of adjuvant Taxotere and Cytoxan chemotherapy (TC): docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 administered intravenously on Day 1 of each 21day cycle Eastern Cooperative Oncology Group Status (ECOG) performance status of ≤ 1 No prior treatment for breast cancer other than surgery Adequate baseline organ function as evidenced by: Hemoglobin ≥ 9 g/dL Absolute neutrophil count ≥ 1.5 x 109 cells/mm3 Platelet count ≥ 100,000 cells/mm3 Serum creatinine ≤ 1.5 x upper limit of normal (ULN) Alkaline phosphatase ≤ 1.5 x ULN No history of other malignancies within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma or squamous cell carcinoma of the skin that have been previously treated with curative intent Women of childbearing potential who commit to using two forms of highly effective nonhormonal contraception either by the subject and/or partner during the study Negative urine pregnancy test at screening Negative urine drug screen (UDS) for drugs of abuse including cotinine (nicotine) at screening Subjects must be capable of understanding the purpose and risks of the study and provide written, voluntary informed consent Preexisting diagnosed psychiatric disorder as defined by The Diagnostic and Statistical Manual (DSM) of Mental Disorders (published by the American Psychiatric Association). Subjects with a diagnosis of depression will be allowed to enter into study as long as they have been treated with medication for ≥ 6 months and/or depression is considered to be well controlled Pregnant or lactating Diabetes Concomitant use of any sleeping agents during the course of the study (Anti anxiety medications will be allowed) Steroid therapy other than the standard prescribed therapy of either of the following during the course of the study: Dexamethasone 412 mg IV on Day 1 of any cycle Dexamethasone 412 mg PO on Day 2 and Day 3 of any cycle Antiestrogen therapy other than the standard prescribed therapy of one of the following: Tamoxifen/Nolvadex 20 mg PO daily Anastrazole/Arimidex 1 mg PO daily Letrozole/Femara 2.5 mg PO daily Exemestane/Aromasin 25 mg PO daily Use of any other antiemetic regimen other than the following (with the exception of PO antiemetics): Emend /Aprepitant150 mg IV on Day 1 of any cycle Aloxi/Palonosetron 0.25 mg IV on Day 1 of any cycle Dexamethasone 8 mg IV on Day 1 of any cycle Dexamethasone 8 mg PO on Day 2 and Day 3 of any cycle Zofran/Ondansetron 12 mg IV on Day 1 of any cycle Kytrile/Granisetron 12 mg IV on Day 1 of any cycle Therapy with any immunomodulatory or immunosuppressive drugs within 6 months prior to enrollment Known history of positive viral serology test for Human Immunodeficiency Virus (HIV1), HBsAG and Hepatitis C antibody Any change in the initially prescribed chemotherapy Use of herbal remedies, dietary supplements or megavitamins, with the exception of a multivitamin Investigator deems the subject to be unable or unwilling to comply with the requirements of the protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Stage I breast cancer</keyword>
	<keyword>Stage II breast cancer</keyword>
	<keyword>Water study</keyword>
	<keyword>'R'</keyword>
	<keyword>Electro-kinetically altered beverage</keyword>
	<keyword>altered beverage</keyword>
	<keyword>Insomnia</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Depression</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
</DOC>